|
|
 Previous Article | Table of Contents | Next Article 
Comparative effects of granulocyte-macrophage colony-stimulating factor
(GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming
peripheral blood progenitor cells for use with autologous bone marrow after
high-dose chemotherapy
WP Peters, G Rosner, M Ross, J Vredenburgh, B Meisenberg, C Gilbert and J Kurtzberg
Duke University Bone Marrow Transplant Program, Durham, NC 27710.
Two hematopoietic colony-stimulating factors, granulocyte colony-
stimulating factor (G-CSF) and granulocyte-macrophage CSF (GM-CSF), have
been shown to accelerate leukocyte and neutrophil recovery after high-dose
chemotherapy and autologous bone marrow (BM) support. Despite their use, a
prolonged period of absolute leukopenia persists during which infections
and other complications of transplantation occur. We collected large
numbers of peripheral blood (PB) progenitors after CSF administration using
either G-CSF or GM-CSF and tested their ability to affect hematopoietic
reconstitution and resource utilization in patients undergoing high-dose
chemotherapy and autologous BM support. Patients with breast cancer or
melanoma undergoing high-dose chemotherapy and autologous BM support were
studied in sequential nonrandomized trials. After identical high-dose
chemotherapy, patients received either BM alone, with no CSF; BM with
either G-CSF or GM-CSF; or BM with G-CSF or GM-CSF and G-CSF or GM-CSF
primed peripheral blood progenitor cells (PBPC). Hematopoietic
reconstitution, as well as resource utilization, was monitored in these
patients. The use of CSF- primed PBPC led to a highly significant reduction
in the duration of leukopenia with a white blood cell (WBC) count under 100
and 200 cells/mL, and neutrophil count under 100 and 200 cells/mL with both
GM- and G-CSF primed PB progenitor cells, compared with the use of the CSF
with BM or with historical controls using BM alone. In addition, the use of
CSF-primed PBPC resulted in a significant reduction in median number of
antibiotics used, days in the Bone Marrow Transplant Unit, and hospital
resources used. Patients receiving G-CSF primed PBPC also experienced a
reduction in the median number of days in the hospital, red blood cell
(RBC) transfusions, platelet transfusions, days on antibiotics, and
discounted hospital charges. Phenotypic analysis of the CSF-primed PBPC
indicated the presence of cells bearing antigens associated with both early
and late hematopoietic progenitor cells. The use of CSF-primed PBPC can
significantly improve hematopoietic recovery after high-dose chemotherapy
and autologous BM support. In addition, the use of G-CSF-primed PBPC was
associated with a significant reduction in hospital resource utilization,
and a reduction in hospital charges.
Volume 81,
Issue 7,
pp. 1709-1719,
04/01/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
F. Fernandez-Aviles, E. Carreras, A. Urbano-Ispizua, M. Rovira, C. Martinez, A. Gaya, M. Granell, L. Ramiro, C. Gallego, A. Hernando, et al.
Case-Control Comparison of At-Home to Total Hospital Care for Autologous Stem-Cell Transplantation for Hematologic Malignancies
J. Clin. Oncol.,
October 20, 2006;
24(30):
4855 - 4861.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Lee, M. Aoki, T. Kondo, K. Kobayashi, K. Okumura, K. Komori, and T. Murohara
Therapeutic Angiogenesis With Intramuscular Injection of Low-Dose Recombinant Granulocyte-Colony Stimulating Factor
Arterioscler Thromb Vasc Biol,
December 1, 2005;
25(12):
2535 - 2541.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. F. Leonard, M. Lind, C. Twelves, R. Coleman, S. van Belle, C. Wilson, J. Ledermann, I. Kennedy, P. Barrett-Lee, T. Perren, et al.
Conventional Adjuvant Chemotherapy Versus Single-Cycle, Autograft-Supported, High-Dose, Late-Intensification Chemotherapy in High-Risk Breast Cancer Patients: A Randomized Trial
J Natl Cancer Inst,
July 21, 2004;
96(14):
1076 - 1083.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Ingram
Counting the True Cost and Value of Medicines
Oncologist,
February 1, 2003;
8(1):
2 - 4.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Cottler-Fox, T. Lapidot, I. Petit, O. Kollet, J. F. DiPersio, D. Link, and S. Devine
Stem Cell Mobilization
Hematology,
January 1, 2003;
2003(1):
419 - 437.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rosu-Myles, L. Gallacher, B. Murdoch, D. A. Hess, M. Keeney, D. Kelvin, L. Dale, S. S. G. Ferguson, D. Wu, F. Fellows, et al.
The human hematopoietic stem cell compartment is heterogeneous for CXCR4 expression
PNAS,
December 19, 2000;
97(26):
14626 - 14631.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Siena, R. Schiavo, P. Pedrazzoli, and C. Carlo-Stella
Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy
J. Clin. Oncol.,
March 13, 2000;
18(6):
1360 - 1377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. P. Peters, R. D. Dansey, J. L. Klein, and R. D. Baynes
High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation in the Treatment of Breast Cancer
Oncologist,
February 1, 2000;
5(1):
1 - 13.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. H. Weaver, K. A. Schulman, B. Wilson-Relyea, R. Birch, W. West, and C. D. Buckner
Randomized Trial of Filgrastim, Sargramostim, or Sequential Sargramostim and Filgrastim After Myelosuppressive Chemotherapy for the Harvesting of Peripheral-Blood Stem Cells
J. Clin. Oncol.,
January 1, 2000;
18(1):
43 - 43.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Korbling
Peripheral Blood Stem Cells: A Novel Source for Allogeneic Transplantation
Oncologist,
April 1, 1997;
2(2):
104 - 104.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L.B. To, D.N. Haylock, P.J. Simmons, and C.A. Juttner
The Biology and Clinical Uses of Blood Stem Cells
Blood,
April 1, 1997;
89(7):
2233 - 2258.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K.W. Lie and L. B. To
Peripheral Blood Stem Cells: Transplantation and Beyond
Oncologist,
February 1, 1997;
2(1):
40 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Aiuti, I.J. Webb, C. Bleul, T. Springer, and J.C. Gutierrez-Ramos
The Chemokine SDF-1 Is a Chemoattractant for Human CD34+ Hematopoietic Progenitor Cells and Provides a New Mechanism to Explain the Mobilization of CD34+ Progenitors to Peripheral Blood
J. Exp. Med.,
January 6, 1997;
185(1):
111 - 120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Elfenbein
Optimizing recovery from aplasia after high-dose therapy and hematopoietic stem cell transplantation
Journal of Oncology Pharmacy Practice,
January 1, 1996;
2(1_suppl):
4 - 10.
[Abstract]
[PDF]
|
|
|
|
|
